SamanTree Medical, a leader in oncologic surgical imaging innovation, today announced promising results from the SHIELD study ...

The company found that the 1 mg dose of Z-endoxifen reduced MBD by 17.3 percentage points, whereas the 2 mg dose achieved a reduction of 23.5 percentage points. Meanwhile, a minimal change of 0.27 ...

Raven-Symoné recently opened up about undergoing surgery at a very young age. In her comments, the actor stated that she did so after receiving advice that a breast reduction procedure would help her ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Raven-Symoné recently opened up about undergoing surgery at a very young age. In her comments, the actor stated that she did so after receiving advice that a breast reduction procedure would help her ...

The 38-year-old actress - who started out as a child on 'The Cosby Show' and then found worldwide fame when she took on the title role of the Disney Channel sitcom 'That's So Raven' - revealed that ...

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

SHIELD study shows reoperation rates dropped from 30% to 10% with use of the Histolog® Scanner, highlighting its potential to improve oncologic surgery and patient outcomes SamanTree Medical, a ...

Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...